Bullish & Foolish
Full MCRB fundamentals All 466 on the Survival Watch

MCRBSeres Therapeutics, Inc.

Is Seres Therapeutics struggling financially?

Yes, by its own account. Seres Therapeutics told the SEC on 5 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern. It generated cash over the last twelve months rather than burning it, so the doubt here is about something other than an empty bank account.

Going concern disclosed May 2026

30/100

Fragile

Cries for help

Nothing in the filings we have read reads as a plea for help.

Signs of a way out

  • Regulatory win

    In December 2024, we received Breakthrough Therapy designation for SER-155 for the reduction of BSIs in patients 18 years and older undergoing allo-HSCT.

    Form 10-Q, filed 5 May 2026. Read it on SEC.gov

Sector
Biotech/Pharma
Market cap
$45.8M
Source filing
10-Q 5 May 2026
Balance sheet
30 Jun 2026

Cash runway

No net burn

This company generated cash over the last twelve months, so there is no burn rate to divide by. Going concern language in this position is usually about debt coming due or a covenant.

What it reported

Cash and short-term investments

$15.6M

What Seres Therapeutics told the SEC

…our common stock. The principal risks and uncertainties affecting our business include the following: We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern. We will need additional funding in order to advance development of our product candidates (including to conduct the Phase 2 study of SER-155 in allo-HSCT) and commercialize our…

Seres Therapeutics, Inc., Form 10-Q, filed 5 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Debt pressure is material Debt is large against the cash on hand while the business generates little to service it, which puts lenders ahead of shareholders in the queue.
  • 10.6% share-count increase The company issued stock. Each share now owns 9.6% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt